| abstract |
Disclosed are methods for treating, preventing and / or managing myeloproliferative disorders. Certain methods include selective cytokine inhibitors, or pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, or prodrugs thereof, alone or with a second active agent and And / or administration in combination with blood or cell transplantation. Certain second active agents have the ability to suppress overproduction of hematopoietic stem cells or to ameliorate one or more of the symptoms of MPD. Also disclosed are pharmaceutical compositions, single unit formulations, and kits suitable for use in the methods of the invention. |